| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
AG 1295 suppresses PDGFR autophosphorylation, membrane autophosphorylation and the IC50 observed in Swiss 3T3 cells are 0.3-0.5 μM and 0.5-1 μM correspondingly [1]. AG1295 (10 μM, 100 μM) greatly reduces cell viability assay in vitro [2]
|
|---|---|
| ln Vivo |
In aortic allograft vascular damage, AG-1295 inhibits tyrosine phosphorylation caused by PDGFR-β, hence reducing neointima. AG1295 (12 mg/kg; intraperitoneal; daily; 14 or 21 days) was found to dramatically reduce interstitial fibrosis, as seen by larger regions stained with Sirius red, a decrease in macrophage counts, ED-A+ fibronectin deposition, and α-Smooth muscle actin-promoting protein cell counts [4].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: rabbit conjunctival fibroblasts Tested Concentrations: 1 μM, 10 μM, 100 μM Incubation Duration: 3 days Experimental Results: Inhibition of PDGF-AA or PDGF -BB-stimulated growth of rabbit conjunctival fibroblasts [2]. PDGF-AA or PDGF-BB stimulates the growth of rabbit conjunctival fibroblasts. |
| Animal Protocol |
Animal/Disease Models: SD (SD (Sprague-Dawley)) rats (240-270 g) [4]
Doses: 12 mg/kg Route of Administration: intraperitoneal (ip) injection; daily; continued for 14 or 21 days Experimental Results: Rat renal interstitial fibers after unilateral obstruction Weakened. |
| References |
|
| Additional Infomation |
6,7-dimethyl-2-phenylquinoxaline is a quinoxaline derivative. It has a role as a geroprotector.
Tyrphostin AG 1295 is a member of the Tyrphostin family of tyrosine kinase inhibitors that inhibits signal transduction through platelet-derived growth factor receptor and selectively attenuates smooth muscle cell growth. (NCI) |
| Molecular Formula |
C16H14N2
|
|---|---|
| Molecular Weight |
234.29600
|
| Exact Mass |
234.115
|
| Elemental Analysis |
C, 82.02; H, 6.02; N, 11.96
|
| CAS # |
71897-07-9
|
| PubChem CID |
2048
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
398.3±37.0 °C at 760 mmHg
|
| Flash Point |
172.4±17.8 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.636
|
| LogP |
3.92
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
272
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1C2C(=CC(C)=C(C)C=2)N=CC=1C1=CC=CC=C1
|
| InChi Key |
FQNCLVJEQCJWSU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14N2/c1-11-8-14-15(9-12(11)2)18-16(10-17-14)13-6-4-3-5-7-13/h3-10H,1-2H3
|
| Chemical Name |
6,7-dimethyl-2-phenylquinoxaline
|
| Synonyms |
AG1295; AG-1295; AG 1295; NSC 380341; Tyrphostin AG 1295.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~266.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2680 mL | 21.3402 mL | 42.6803 mL | |
| 5 mM | 0.8536 mL | 4.2680 mL | 8.5361 mL | |
| 10 mM | 0.4268 mL | 2.1340 mL | 4.2680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
